These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30990412)

  • 1. Effects of denosumab on hypercalcemia and bone mineral density loss in kidney transplant recipients
.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Yagisawa T
    Clin Nephrol; 2019 Jul; 92(1):1-8. PubMed ID: 30990412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follow-Up of Bone Mineral Density Changes in de novo Kidney Transplant Recipients Treated with Two Doses of the Receptor Activator of Nuclear Factor κB Ligand Inhibitor Denosumab.
    Kobel C; Frey D; Graf N; Wüthrich RP; Bonani M
    Kidney Blood Press Res; 2019; 44(5):1285-1293. PubMed ID: 31614356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of denosumab on bone metabolism and bone mineral density in kidney transplant patients: a systematic review and meta-analysis.
    Thongprayoon C; Acharya P; Aeddula NR; Torres-Ortiz A; Bathini T; Sharma K; Ungprasert P; Watthanasuntorn K; Suarez MLG; Salim SA; Kaewput W; Chenbhanich J; Mao MA; Cheungpasitporn W
    Arch Osteoporos; 2019 Mar; 14(1):35. PubMed ID: 30852679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency.
    Miyaoka D; Imanishi Y; Ohara M; Hayashi N; Nagata Y; Yamada S; Mori K; Emoto M; Inaba M
    Osteoporos Int; 2019 Jan; 30(1):241-249. PubMed ID: 30187112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Denosumab on Bone Metabolic Markers and Bone Mineral Density in Patients Treated with Glucocorticoids.
    Sawamura M; Komatsuda A; Togashi M; Wakui H; Takahashi N
    Intern Med; 2017; 56(6):631-636. PubMed ID: 28321061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
    Nakatsukasa K; Koyama H; Ouchi Y; Ono H; Sakaguchi K; Matsuda T; Kato M; Ishikawa T; Yamada K; Yoshimura M; Koizumi K; Sakurai T; Shigematsu H; Takahashi S; Taira S; Suzuki M; Narui K; Niikura N; Hasegawa Y; Miura D; Konishi E; Taguchi T;
    Breast Cancer; 2019 Jan; 26(1):106-112. PubMed ID: 30054855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive Power of Bone Turnover Biomarkers to Estimate Bone Mineral Density after Kidney Transplantation with or without Denosumab: A post hoc Analysis of the POSTOP Study.
    Heimgartner N; Graf N; Frey D; Saleh L; Wüthrich RP; Bonani M
    Kidney Blood Press Res; 2020; 45(5):758-767. PubMed ID: 32998144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis.
    Rajput S; Dutta A; Rajender S; Mithal A; Chattopadhyay N
    Front Endocrinol (Lausanne); 2023; 14():1098841. PubMed ID: 36817591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies.
    Thongprayoon C; Acharya P; Acharya C; Chenbhanich J; Bathini T; Boonpheng B; Sharma K; Wijarnpreecha K; Ungprasert P; Gonzalez Suarez ML; Cheungpasitporn W
    Osteoporos Int; 2018 Aug; 29(8):1737-1745. PubMed ID: 29713798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
    McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
    Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined teriparatide and denosumab therapy accelerates spinal fusion following posterior lumbar interbody fusion.
    Ide M; Yamada K; Kaneko K; Sekiya T; Kanai K; Higashi T; Saito T
    Orthop Traumatol Surg Res; 2018 Nov; 104(7):1043-1048. PubMed ID: 30179720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury.
    Gifre L; Vidal J; Carrasco JL; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
    Osteoporos Int; 2016 Jan; 27(1):405-10. PubMed ID: 26423406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
    Nakamura Y; Suzuki T; Kato H
    Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Denosumab on Peripheral Compartmental Bone Density, Microarchitecture and Estimated Bone Strength in De Novo Kidney Transplant Recipients.
    Bonani M; Meyer U; Frey D; Graf N; Bischoff-Ferrari HA; Wüthrich RP
    Kidney Blood Press Res; 2016; 41(5):614-622. PubMed ID: 27622692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
    Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
    J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism.
    Bergua C; Torregrosa JV; Fuster D; Gutierrez-Dalmau A; Oppenheimer F; Campistol JM
    Transplantation; 2008 Aug; 86(3):413-7. PubMed ID: 18698244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs.
    Iwamoto N; Okamoto M; Tsuji S; Endo Y; Takatani A; Shimizu T; Umeda M; Fukui S; Sumiyoshi R; Igawa T; Koga T; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Nakamura H; Origuchi T; Eguchi K; Ueki Y; Kawakami A
    J Bone Miner Metab; 2019 May; 37(3):554-562. PubMed ID: 30187273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women.
    Augoulea A; Tsakonas E; Triantafyllopoulos I; Rizos D; Armeni E; Tsoltos N; Tournis S; Deligeoroglou E; Antoniou A; Lambrinoudaki I
    J Musculoskelet Neuronal Interact; 2017 Mar; 17(1):444-449. PubMed ID: 28250248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibandronate in stable renal transplant recipients with low bone mineral density on long-term follow-up.
    Tillmann FP; Schmitz M; Jäger M; Krauspe R; Rump LC
    Int Urol Nephrol; 2016 Feb; 48(2):279-86. PubMed ID: 26498632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.
    Segaud N; Legroux I; Hazzan M; Noel C; Cortet B
    Osteoporos Int; 2018 May; 29(5):1165-1175. PubMed ID: 29500526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.